Advent Life Sciences is a trans-Atlantic venture capital firm founded in 2006 (with a formal 2010 spin-out from Advent. See sector focus and contact routes.
Advent Life Sciences is a trans-Atlantic venture capital firm founded in 2006 (with a formal 2010 spin-out from Advent Venture Partners) that specializes in building innovative life sciences businesses across the UK, Europe, and the USA. The firm targets early- to mid-stage companies in biotechnology, pharmaceuticals, medical technology, digital health, new drug discovery, diagnostics, and vaccines. While specific check sizes and lead/follow behavior are not explicitly detailed in available sources, the firm manages hundreds of millions in assets, including a recent $285 million fundraising across its third flagship fund and an impact fund. Notable portfolio companies include Arrakis Therapeutics, KaNDy Therapeutics, F2G, and Algeta, which focus on addressing unmet medical needs with first-in-class or best-in-class solutions. Advent distinguishes itself through a hands-on, strategic partnership model that combines scientific rigor with execution support to accelerate therapies from research to market approval. The firm does not appear to publish distinctive public writing or a unique point of view beyond its stated mission to back visionary innovators in
Every field above is read from the StartupFundraising firm directory — disclosed location, recorded investments and stated focus — and re-checked as filings arrive. Founders pair it with investors in London when building a target list.
Investors like Advent Life Sciences · Full investor directory · Investor access · Company funding database